Perspective Therapeutics (CATX) Net Margin Growth (5y) (2015 - 2023)
Powered by 
Analysis
Perspective Therapeutics (CATX) Net Margin Growth (5y) (2015 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 54,787.00 |
| Sep 30, 2023 | -41,310.00 |
| Jun 30, 2023 | -46,220.00 |
| Mar 31, 2023 | -418.00 |
| Sep 30, 2022 | 2,285.00 |
| Jun 30, 2022 | 9,725.00 |
| Mar 31, 2022 | 6,003.00 |
| Dec 31, 2021 | 8,428.00 |
| Sep 30, 2021 | 5,137.00 |
| Jun 30, 2021 | 6,692.00 |
| Mar 31, 2021 | 7,135.00 |
| Dec 31, 2020 | 7,372.00 |
| Sep 30, 2020 | 5,109.00 |
| Jun 30, 2020 | 2,513.00 |
| Mar 31, 2020 | 6,354.00 |
| Dec 31, 2019 | 4,461.00 |
| Sep 30, 2019 | 4,029.00 |
| Jun 30, 2019 | 11,991.00 |
| Mar 31, 2019 | 12,518.00 |
| Dec 31, 2018 | 1,128.00 |